Immunologic functions as prognostic indicators in melanoma

Molecular Oncology

Volumn 5, Issue 2, 2011, Pages 183-189

  Bouwhuis, Marna G ^a   ten Hagen, Timo L M ^a   Eggermont, Alexander M M ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Absolute lymphocyte count; Autoimmunity; CRP; HLA; Immunotherapy; Melanoma; Prognosis; White blood cell count

Indexed keywords

AMYLOID A PROTEIN; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FERRITIN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B44 ANTIGEN; HLA DQ ANTIGEN; HLA DQ1 ANTIGEN; HLA DR ANTIGEN; IMMUNE TRANSFER FACTOR; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; LACTATE DEHYDROGENASE; PROTEIN S100B; THYROGLOBULIN ANTIBODY; TICILIMUMAB;

AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DERMATITIS; DIARRHEA; FATIGUE; GASTROINTESTINAL DISEASE; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; LEUKOCYTE COUNT; LOW DRUG DOSE; MASS SPECTROMETRY; MELANOMA; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RASH; REVIEW; TREATMENT RESPONSE; TUMOR IMMUNITY; VITILIGO;

EID: 79955471352     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.01.004     Document Type: Review

References (66)

1. Anderson J.R., Cain K.C., Gelber R.D. Analysis of survival by tumor response. J. Clin. Oncol. 1983, 1:710-719.
2. Atkins M.B., Mier J.W., Parkinson D.R., Gould J.A., Berkman E.M., Kaplan M.M. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N. Engl. J. Med. 1988, 318:1557-1563.
3. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 1999, 17:2105-2116.
4. Attia P., Phan G.Q., Maker A.V., Robinson M.R., Quezado M.M., Yang J.C., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005, 23:6043-6053.
5. Avril M.F., Aamdal S., Grob J.J., Hauschild A., Mohr P., Bonerandi J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J. Clin. Oncol. 2004, 22:1118-1125.
6. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009, 27:6199-6206.
7. Bernengo M.G., Lisa F., Meregalli M., De Matteis A., Zina G. The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-up. Cancer 1983, 52:1841-1848.
8. Boasberg P.D., Hoon D.S., Piro L.D., Martin M.A., Fujimoto A., Kristedja T.S., et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J. Invest. Dermatol. 2006, 126:2658-2663.
9. Bouwhuis, M.G., Suciu, S., Testori, A., Kruit, W.H., Sales, F., Patel, P., et al., Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies-EORTC 18991. J. Clin. Oncol. 28, 2460-2466.
10. Bouwhuis M.G., Suciu S., Collette S., Aamdal S., Kruit W.H., Bastholt L., et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J. Natl. Cancer Inst. 2009, 101:869-877.
11. Bowne W.B., Srinivasan R., Wolchok J.D., Hawkins W.G., Blachere N.E., Dyall R., et al. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 1999, 190:1717-1722.
12. Camacho L.H., Antonia S., Sosman J., Kirkwood J.M., Gajewski T.F., Redman B., et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 2009, 27:1075-1081.
13. Davis J.L., Ripley R.T., Frankel T.L., Maric I., Lozier J.N., Rosenberg S.A. Paraneoplastic granulocytosis in metastatic melanoma. Melanoma Res. 2010, 20:326-329.
14. Deichmann M., Kahle B., Moser K., Wacker J., Wust K. Diagnosing melanoma patients entering American Joint Committee on cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br. J. Cancer 2004, 91:699-702.
15. Downey S.G., Klapper J.A., Smith F.O., Yang J.C., Sherry R.M., Royal R.E., et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 2007, 13:6681-6688.
16. Eggermont A.M., Kirkwood J.M. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur. J. Cancer 2004, 40:1825-1836.
17. Eggermont A.M., Schadendorf D. Melanoma and immunotherapy. Hematol. Oncol. Clin. North Am. 2009, 23:547-564,. ix-x.
18. Eggermont A.M., Suciu S., MacKie R., Ruka W., Testori A., Kruit W., et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005, 366:1189-1196.
19. Findeisen P., Zapatka M., Peccerella T., Matzk H., Neumaier M., Schadendorf D., et al. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J. Clin. Oncol. 2009, 27:2199-2208.
20. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 2006, 354:709-718.
21. Gogas H., Kirkwood J.M., Falk C.S., Dafni U., Sondak V.K., Tsoutsos D., et al. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 2010, 116:4326-4333.
22. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 2005, 23:515-548.
23. Hansson J., Aamdal S., Bastholt L., Hernberg M., Nilsson B., Stierner U., et al. Results of the Nordic randomised adjuvant trial of intermediate-dose interferon alfa-2b in high-risk melanoma. Eur. J. Cancer 2007, 6(Supplement 5):4.
24. Hara I., Takechi Y., Houghton A.N. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J. Exp. Med. 1995, 182:1609-1614.
25. Hersh, E.M., O'Day, S.J., Powderly, J., Khan, K.D., Pavlick, A.C., Cranmer, L.D. et al., A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest. New Drugs.
26. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
27. Imran A., Neelam F., Tariq M. Incidence of circulating antinuclear antibodies in cancer patients. Indian J. Med. Sci. 2003, 57:113-116.
28. Kalbfleisch J.D., Prentice R.L. The Survival Analysis of Failure Time Data 2002, Wiley Inter-Science, New-Jersey. second ed.
29. Kirkwood J.M., Lorigan P., Hersey P., Hauschild A., Robert C., McDermott D., et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 2010, 16:1042-1048.
30. Krouse R.S., Royal R.E., Heywood G., Weintraub B.D., White D.E., Steinberg S.M., et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J. Immunother Emphasis Tumor Immunol. 1995, 18:272-278.
31. Kruit W.H., Bolhuis R.L., Goey S.H., Jansen R.L., Eggermont A.M., Batchelor D., et al. Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J. Clin. Oncol. 1993, 11:921-924.
32. Ku, G.Y., Yuan, J., Page, D.B., Schroeder, S.E., Panageas, K.S., Carvajal, R.D., et al., Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116, 1767-1775.
33. Lee J.E., Reveille J.D., Ross M.I., Platsoucas C.D. HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int. J. Cancer 1994, 59:510-513.
34. Lee J.E., Lu M., Mansfield P.F., Platsoucas C.D., Reveille J.D., Ross M.I. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II. Cancer 1996, 78:758-763.
35. Lee J.E., Abdalla J., Porter G.A., Bradford L., Grimm E.A., Reveille J.D., et al. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann. Surg. Oncol. 2002, 9:587-593.
36. Marincola F.M., Shamamian P., Rivoltini L., Salgaller M., Cormier J., Restifo N.P., et al. HLA associations in the antitumor response against malignant melanoma. J. Immunother Emphasis Tumor Immunol. 1995, 18:242-252.
37. Negrier S., Escudier B., Gomez F., Douillard J.Y., Ravaud A., Chevreau C., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann. Oncol. 2002, 13:1460-1468.
38. O'Day S.J., Maio M., Chiarion-Sileni V., Gajewski T.F., Pehamberger H., Bondarenko I.N., et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 2010.
39. Phan G.Q., Attia P., Steinberg S.M., White D.E., Rosenberg S.A. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 2001, 19:3477-3482.
40. Ramirez-Montagut T., Turk M.J., Wolchok J.D., Guevara-Patino J.A., Houghton A.N. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 2003, 22:3180-3187.
41. Reuben J.M., Lee B.N., Li C., Gomez-Navarro J., Bozon V.A., Parker C.A., et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006, 106:2437-2444.
42. Rosenberg S.A., White D.E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother Emphasis Tumor Immunol. 1996, 19:81-84.
43. Rosenberg S.A., Yang J.C., White D.E., Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 1998, 228:307-319.
44. Rubin J.T., Day R., Duquesnoy R., Simonis B., Adams S., Lee J., et al. HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2. Ther. Immunol. 1995, 2:1-6.
45. Satzger I., Meier A., Schenck F., Kapp A., Hauschild A., Gutzmer R. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int. J. Cancer 2007, 121:2562-2566.
46. Scalzo S., Gengaro A., Boccoli G., Masciulli R., Giannella G., Salvo G., et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. Eur. J. Cancer 1990, 26:1152-1156.
47. Scheibenbogen C., Keilholz U., Mytilineos J., Suciu S., Manasterski M., Hunstein W. HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2). Melanoma Res. 1994, 4:191-194.
48. Schmidt H., Bastholt L., Geertsen P., Christensen I.J., Larsen S., Gehl J., et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br. J. Cancer 2005, 93:273-278.
49. Schmidt H., Suciu S., Punt C.J., Gore M., Kruit W., Patel P., et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on cancer Stage IV Melanoma: results of the EORTC 18951 biochemotherapy trial. J. Clin. Oncol. 2007, 25:1562-1569.
50. Shovman O., Gilburd B., Barzilai O., Shinar E., Larida B., Zandman-Goddard G., et al. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann. N. Y Acad. Sci. 2005, 1050:380-388.
51. Solans-Laque R., Perez-Bocanegra C., Salud-Salvia A., Fonollosa-Pla V., Rodrigo M.J., Armadans L., et al. Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes. Lupus 2004, 13:159-164.
52. Stam T.C., Swaak A.J., Kruit W.H., Eggermont A.M. Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b. Eur J Clin Invest 2002, 32(Suppl. 1):79-83.
53. Stuckert J.J., Tarhini A.A., Lee S., Sander C., Kirkwood J.M. Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696. J Clin Oncol 2007, 25(suppl):8506.
54. Tan E.M., Feltkamp T.E., Smolen J.S., Butcher B., Dawkins R., Fritzler M.J., et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997, 40:1601-1611.
55. Tartour E., Dorval T., Mosseri V., Deneux L., Mathiot C., Brailly H., et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br. J. Cancer 1994, 69:911-913.
56. Tartour E., Blay J.Y., Dorval T., Escudier B., Mosseri V., Douillard J.Y., et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J. Clin. Oncol. 1996, 14:1697-1703.
57. Teft W.A., Kirchhof M.G., Madrenas J. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 2006, 24:65-97.
58. Trcka J., Moroi Y., Clynes R.A., Goldberg S.M., Bergtold A., Perales M.A., et al. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity 2002, 16:861-868.
59. Turk M.J., Wolchok J.D., Guevara-Patino J.A., Goldberg S.M., Houghton A.N. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 2002, 188:122-135.
60. Uchi H., Stan R., Turk M.J., Engelhorn M.E., Rizzuto G.A., Goldberg S.M., et al. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv. Immunol. 2006, 90:215-241.
61. Weber J.S., O'Day S., Urba W., Powderly J., Nichol G., Yellin M., et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 2008, 26:5950-5956.
62. Weber J., Thompson J.A., Hamid O., Minor D., Amin A., Ron I., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 2009, 15:5591-5598.
63. Weijl N.I., Van der Harst D., Brand A., Kooy Y., Van Luxemburg S., Schroder J., et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J. Clin. Oncol. 1993, 11:1376-1383.
64. West W.H., Tauer K.W., Yannelli J.R., Marshall G.D., Orr D.W., Thurman G.B., et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 1987, 316:898-905.
65. Wolchok J.D., Neyns B., Linette G., Negrier S., Lutzky J., Thomas L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010, 11:155-164.
66. Zhang S., Bernard D., Khan W.I., Kaplan M.H., Bramson J.L., Wan Y. CD4+ T-cell-mediated anti-tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis. Eur. J. Immunol. 2009, 39:1252-1259.